Epigallocatechin‐3‐gallate treatment reduces thermal hyperalgesia after spinal cord injury by down‐regulating RhoA expression in mice

Álvarez-Pérez, Beltrán; Homs, Judit; Bosch-Mola, Marc; Puig, Teresa; Reina, Francisco; Verdú, Enrique; Boadas-Vaello, Pere

doi:10.1002/ejp.722

Cited by 30 publications

(30 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the pro-inflammatory cytokines TNF-α and IL-1β have been associated with central neuropathic pain after spinal cord injury 33 – 35 , we also assessed whether their expression in spinal cord is attenuated in σ 1 R KO mice 28 days after injury. The ANOVA analysis revealed significant differences between groups in both TNF-α and IL-1β expression (p < 0.05).…”

Section: Resultsmentioning

confidence: 99%

“…Pro-inflammatory cytokines play a major role in neuron–glia cross-talk in neuroinflammatory processes but they also play a role in pain and central sensitization phenomena in the context of neuropathic pain 33 – 35 , 45 , 68 – 77 . In particular, spinal TNF-α and IL-1β are involved in mechanisms underlying the development and maintenance of neuropathic pain by promoting synaptic plasticity and central sensitization.…”

Section: Discussionmentioning

confidence: 99%

“…As a mechanistic correlate, given the role of σ 1 R in modulating central sensitization phenomena 14 , 30 , we also investigated phosphorylation in the spinal cord of the glutamate N -methyl-D-aspartate (NMDA) receptor and the extracellular signal-regulated kinase (ERK1/2); both of which are reportedly involved in central sensitization 19 and hypersensitivity in neuropathic pain conditions 31 , 32 . Moreover, considering the role of pro-inflammatory cytokines in the pathophysiology of neuropathic pain after SCI, the expression of TNF-α and IL-1β 33 – 35 was investigated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice

Castany

Gris

Vela

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Sigma-1 receptor (σ1R) knockout (KO) CD1 mice, generated by homologous recombination, and separate pharmacological studies in wild type (WT) mice were done to investigate the role of this receptor in the development of pain-related behaviours (thermal hyperalgesia and mechanical allodynia) in mice after spinal cord contusion injury (SCI) – a model of central neuropathic pain. The modulatory effect of σ1R KO on extracellular mediators and signalling pathways in the spinal cord was also investigated. In particular, changes in the expression of inflammatory cytokines (tumour necrosis factor TNF-α, interleukin IL-1β) and both the expression and activation (phosphorylation) of the N-methyl-D-aspartate receptor subunit 2B (NR2B-NMDA) and extracellular signal-regulated kinases (ERK1/2) were analysed. Compared with WT mice, both mechanical and thermal hypersensitivity were attenuated in σ1R KO mice following SCI. Accordingly, treatment of WT mice with the σ1R antagonist MR309 (previously developed as E-52862; S1RA) after SCI exerted antinociceptive effects (i.e. reduced mechanical allodynia and thermal hyperalgesia). Attenuated nociceptive responses in σ1R KO were accompanied by reduced expression of TNF- α and IL-1β as well as decreased activation/phosphorylation of NR2B-NMDA receptors and ERK1/2. These findings suggest that σ1R may modulate central neuropathic pain and point to regulation of sensitization-related phenomena as a possible mechanism.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice

Castany

Gris

Vela

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Peripheral analgesic effects of EGCG are related to the suppression of CCR2, IL-1β, and TNF-α mRNA expression in the DRG in a model of OA [151] and through down-regulation of CX3CL1 protein in the spinal cord in a CCI-induced neuropathic pain [146]. In terms of spinal effects, EGCG decreases TNF-α expression in the spinal cord in mouse models of bone cancer-caused pain [152] and reduces glial cell activation via inhibition of fatty acid synthase (FASN), Ras homologue gene family member A (RhoA), and TNF-α in a model of spinal cord injury (SCI) [153].…”

Section: Flavanols Flavan-3-ols or Catechinsmentioning

confidence: 99%

Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development

et al. 2020

View full text Add to dashboard Cite

Pathological pain can be initiated after inflammation and/or peripheral nerve injury. It is a consequence of the pathological functioning of the nervous system rather than only a symptom. In fact, pain is a significant social, health, and economic burden worldwide. Flavonoids are plant derivative compounds easily found in several fruits and vegetables and consumed in the daily food intake. Flavonoids vary in terms of classes, and while structurally unique, they share a basic structure formed by three rings, known as the flavan nucleus. Structural differences can be found in the pattern of substitution in one of these rings. The hydroxyl group (-OH) position in one of the rings determines the mechanisms of action of the flavonoids and reveals a complex multifunctional activity. Flavonoids have been widely used for their antioxidant, analgesic, and anti-inflammatory effects along with safe preclinical and clinical profiles. In this review, we discuss the preclinical and clinical evidence on the analgesic and anti-inflammatory proprieties of flavonoids. We also focus on how the development of formulations containing flavonoids, along with the understanding of their structure-activity relationship, can be harnessed to identify novel flavonoid-based therapies to treat pathological pain and inflammation.

show abstract

“…In the last two years, many research studies, focusing on the identification of drugs potentially effective in SCI treatment, have been published [ 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ,…”

Section: Overview Of Current Pharmacological Approaches For the Trmentioning

confidence: 99%

Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury

et al. 2017

View full text Add to dashboard Cite

The complex pathophysiology of spinal cord injury (SCI) may explain the current lack of an effective therapeutic approach for the regeneration of damaged neuronal cells and the recovery of motor functions. A primary mechanical injury in the spinal cord triggers a cascade of secondary events, which are involved in SCI instauration and progression. The aim of the present review is to provide an overview of the therapeutic neuro-protective and neuro-regenerative approaches, which involve the use of nanofibers as local drug delivery systems. Drugs released by nanofibers aim at preventing the cascade of secondary damage (neuro-protection), whereas nanofibrous structures are intended to re-establish neuronal connectivity through axonal sprouting (neuro-regeneration) promotion, in order to achieve a rapid functional recovery of spinal cord.

show abstract

Epigallocatechin‐3‐gallate treatment reduces thermal hyperalgesia after spinal cord injury by down‐regulating RhoA expression in mice

Abstract: These findings suggest that at short time EGCG treatment reduces thermal hyperalgesia and gliosis via FASN and RhoA pathway, causing a decrease in cytokines in spinal cord.

Cited by 30 publications

References 66 publications

Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice

Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice

Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development

Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury

Contact Info

Product

Resources

About